Content of the article

MISSISSAUGA, Ontario, Feb. 15 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces progress in expanding the manufacturing capacity of its portfolio of quality assessment products (“QAP™“) and his “DxTM™brand’s viral medium – through the renovation and outfitting of its second and third manufacturing sites in Mississauga, Ontario.

First, the final lab at Microbix’s second manufacturing site, at 235 Watline Ave., is now validated to accommodate larger-scale, automated manufacturing of FLOQSwab®Liquid-based and liquid-format QAPs, as well as the ongoing production of DxTM. This validation completes the construction of this site, which now contains two production laboratories and a QC laboratory, as well as the majority of Microbix’s administrative offices.

Content of the article

Second, renovations have now begun on Microbix’s third location, at 275 Watline Ave. This site is being reorganized to accommodate larger scale production of DxTM and construction will be largely completed in the current fiscal quarter. As a first step, Microbix’s high-throughput, semi-automated production process will be installed at this site, which will be quickly followed by more automated production as soon as the necessary equipment is received and validated for use, expected during the quarter ending June 30, 2022 .

The objective of the construction and equipment of these two sites is to multiply by five to ten the production capacities of QAPs and DxTM compared to current levels. For QAPs, producing in such large quantities will allow FLOQSwab-based QAPs to be better manufactured as kit controls for major diagnostic test manufacturers. For DxTM, increased production will allow Microbix to offer strategic quantities of this viral vehicle to governments and private industry buyers beyond Ontario. These initiatives were supported by funding from the Ontario Together Fund (OTF) of the Ontario Ministry of Economic Development, Job Creation and Trade (MEDJCT) and the Federal Economic Development Agency for Southern Ontario (FedDev Ontario).

Content of the article

Microbix now occupies approximately 35,000 square feet at its three adjacent locations at 235, 265 and 275 Watline Ave. in Mississauga, Ontario, Canada. The majority of the space within its sites is devoted to the manufacturing of test kit ingredients (antigens), DxTM and QAP. More than 100 skilled staff work to manufacture Microbix products, which are essential to supporting public health in Ontario, across Canada and around the world. Fiscal 2021 sales reached C$18.6 million and are expected to increase significantly for fiscal 2022 and beyond.

Dr. Ken Hughes, COO of Microbix, said, “Our manufacturing spaces at 235 Watline were designed to support our near-term scaling goals for QIPs. We are fully committed to enabling Microbix to create QAPs at the volumes needed to support testers globally. For DxTM, we are commissioning custom designed production and warehousing spaces at 275 Watline. The dedication of our third site to the production of DxTM aims to provide Ontarians and Canadians with a secure and strategic supply of this vital patient specimen collection device.

Content of the article

About Microbix Biosystems
Microbix develops proprietary biotechnology solutions for human health and well-being, with approximately 100 skilled employees and sales of nearly C$2.0 million per month. It manufactures a wide range of critical biological materials for the global diagnostics industry, including antigens for immunoassays and its Quality Laboratory Assessment Products (QAPs™) that support clinical laboratory proficiency testing, enable the development and validation of tests, or help ensure the quality of clinical diagnosis. workflow. Microbix antigens enable antibody testing from more than 100 international diagnostic companies, while its QAPs are sold to clinical laboratory accreditation bodies, diagnostic companies and clinical laboratories. Microbix QAPs are now available in over 30 countries, distributed by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International Distribution SpA., Labquality Oy, The Medical Supply Company of Ireland, R-Biopharm AG , SDT Molecular Pte Ltd, Seegene Canada Inc. and Thomas Scientific LLC. Microbix is ​​ISO 9001 and 13485 accredited, registered with the US FDA, registered with the Australian TGA, approved by Health Canada and provides CE marked products.

Content of the article

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, including Viral Transport Medium (DxTM™) to stabilize patient samples for molecular diagnostic laboratory testing and Kinlytic® Urokinase, a biological thrombolytic drug used to treat blood clots. . Microbix is ​​listed on the TSX and OTCQX and is headquartered in Mississauga, Ontario, Canada.

Forward-looking information
This press release contains “forward-looking information” as that term is defined under applicable securities laws. Forward-looking information includes, but is not limited to, a discussion of production capacity or plant expansion and their adequacy or timing, Microbix’s business activities and results, its objectives or prospects, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control cost, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising additional capital on terms acceptable or at all, and other similar statements regarding anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. All statements are made as of the date of this press release and represent the judgment of the Company as of the date of this new press release, and the Company undertakes no obligation to update or change any forward-looking information.

Please visit www.microbix.com or www.sedar.com for the latest Microbix news and filings.

For more information, please contact Microbix at:

Copyright © 2022 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic® and QAPs™ are registered trademarks of Microbix Biosystems Inc.
FLOQ® and FLOQSwab® are registered trademarks of Copan Italia SpA